NCT01024504 - Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Oxaliplatin

Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles

DRUG

Capecitabine

Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles

DRUG

Bevacizumab

Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles

Trial Locations (6)

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

Air Forces Military Hospital of Athens, Athens

IASO General Hospital of Athens, 1st Dep of Medical Oncology, Athens

Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens

State General Hospital of Larissa, Larissa

Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki